Study guide
2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness
ACRP Certified Professional ACRP-CP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: GCP Principles, Roles & Delegation
1.1 The Eleven ICH E6(R3) Principles of GCP & Guideline Structure 1.2 Sponsor & Investigator Responsibilities and Delegation of Authority 1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL) 1.4 CRO Oversight, Vendor Management & Transfer of Regulatory Obligations (TORO)
2 Chapter 2: Essential Records, Source Documentation & Data Confidentiality
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C) 2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness 2.3 Source Documentation, ALCOAC Principles & Medical Record Standards 2.4 Confidentiality, Privacy & Protection of Participant Personal Information
3 Chapter 3: Monitoring, Quality Management & Audits
3.1 Risk-Based Quality Management (RBQM) & Quality Management Systems (QMS) 3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out 3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR) 3.4 Quality Audits, Regulatory Inspections, Non-Compliance & Root Cause Analysis / CAPA
4 Chapter 4: Site Feasibility, Start-Up, Facilities & Laboratory Operations
4.1 Site Feasibility Assessment, Capability Analysis & Investigator Selection 4.2 Contractual Agreements: Clinical Trial Agreements, Budgets, Indemnification & Financial Arrangements 4.3 Site Initiation Preparation, System Access & Regulatory Greenlight 4.4 Protocol Review, Operational Feasibility & Institutional Approvals 4.5 Site Facilities, Equipment Maintenance, Calibration & Trial Supplies 4.6 Biological Samples & Hazardous Goods: Collection, Storage, Disposal & Shipment
5 Chapter 5: Subject Recruitment, Retention & Study Visits
5.1 Subject Recruitment Strategies, Advertising Guidelines & Ethical Constraints 5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence 5.3 Subject Retention, Compliance, Visit Scheduling & Protocol Window Management 5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
6 Chapter 6: Protocol Compliance, Deviations & Site Close-Out
6.1 Protocol Compliance, Waivers vs. Violations & Deviation Management 6.2 Investigational Site Close-Out Activities & Final Reconciliations 6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities
7 Chapter 7: Research Ethics, Vulnerable Populations & Research Integrity
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki 7.2 Ethical Principles: Beneficence, Non-Maleficence, Autonomy, Justice & Equipoise 7.3 Vulnerable Populations (Pediatrics, Pregnant Women, Prisoners, Cognitively Impaired, Economically Disadvantaged) 7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
8 Chapter 8: Informed Consent & Institutional Review Boards (IRB/IEC)
8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements 8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements 8.3 IRB/IEC Composition, Functions, Review Types (Full, Expedited, Exempt) & Continuing Review
9 Chapter 9: Safety Reporting & Adverse Event Management (ICH E2A)
9.1 Adverse Events (AE) vs. Adverse Drug Reactions (ADR) & Serious Adverse Events (SAE) Definitions 9.2 Causality Assessment, Expectedness, Reference Safety Information (RSI) & SUSARs 9.3 Expedited Reporting Timelines (7-day fatal/life-threatening, 15-day other serious) & Periodic Safety Updates (DSUR)
10 Chapter 10: Investigational Product (IP) Management & Accountability
10.1 Investigational Product Lifecycle, Labeling, Packaging & Blinding Procedures 10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody 10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures 10.4 Emergency Unblinding (Code Breaking) Protocols & Subject Safety Procedures
11 Chapter 11: Regulatory Frameworks, Submissions & Product Reference Information
11.1 Stakeholders, Regulatory Institutions & Global Frameworks in Clinical Research 11.2 Protocol Submission, Approval & Amendment Processes 11.3 Investigator's Brochure, Instructions for Use & Reference Product Information 11.4 Regulatory Reporting Requirements Before and After Marketing Authorisation
12 Chapter 12: Clinical Data Management, EDC & Electronic Records
12.1 Electronic Data Capture (EDC), eCRF Design & Clinical Data Management Systems (CDMS) 12.2 Computerised Systems, Data Governance & Audit Trails (ICH E6(R3) Annex 1 §4) 12.3 Data Validation, Edit Checks, Discrepancy / Query Management & Resolution 12.4 Medical Coding (MedDRA, WHO Drug), SAE Reconciliation, Data Transfer & Database Lock
13 Chapter 13: Trial Design, Biostatistics, Data Monitoring & Transparency
13.1 Phases of Clinical Research (Phase 0, I, II, III, IV) & Translational Medicine 13.2 Study Designs: Parallel, Crossover, Factorial, Adaptive & Non-Inferiority / Equivalence 13.3 Randomization Schemes, Stratification, Blinding Methods & Minimizing Bias 13.4 Endpoints (Primary, Secondary, Surrogate, Composite), Sample Size & Biostatistical Concepts (p-values, CI, ITT vs PP) 13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones 13.6 Trial Registration, Results Transparency & Communicating Results to Participants
2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness
Key Takeaways Explain This Topic AI
The Trial Master File (TMF) Reference Model, maintained by the DIA, establishes the standardized taxonomy of Zones, Sections, and Artifacts universally adopted across the biopharmaceutical industry.
The Sponsor TMF and the Investigator Site File (ISF) / Regulatory Binder maintain a complementary, dual-custody structure that independently demonstrates trial integrity from both organizational perspectives.
Under 21 CFR Part 11 and EU Annex 11, electronic TMF (eTMF) and eISF systems must enforce robust audit trails, role-based access control, cryptographic e-signatures, and system validation.
Inspection readiness requires continuous contemporaneous filing; trial documentation must tell a complete, standalone story capable of reconstructing every trial event without oral explanation.
Top inspection findings on Form FDA 483 include unauthorized protocol deviations, failure to report adverse events, missing or expired staff credentials, and lapses in investigational product accountability.
Last updated: August 2026
2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness
Exam scope note: This section cites national regulations (for example US Code of Federal Regulations provisions) because they shape day-to-day practice. ACRP states the ACRP-CP exam is referenced only to ICH Guidelines and that no country-specific framework is tested. Treat those citations as professional context; the provision examined here is ICH E6(R3) Appendix C , together with Annex 1 sections 2.12 (investigator records) and 3.16 (sponsor data and records) .
ACRP-CP Exam Focus: The Trial Master File (TMF) is not merely a filing cabinet—it is the definitive legal record of a clinical trial. Candidates must understand the DIA TMF Reference Model structure, the precise operational differences between the Sponsor TMF and the Investigator Site File (ISF) (often referred to as the Regulatory Binder), electronic system standards (21 CFR Part 11), and the practical requirements for maintaining continuous "inspection readiness."
1. The DIA TMF Reference Model Architecture
The Drug Information Association (DIA) TMF Reference Model is the globally accepted standard taxonomy for organizing clinical trial documentation. It structures trial documents into a standardized three-tier hierarchy: TMF Structure = Zones (Top Level) ⟶ Sections (Mid Level) ⟶ Artifacts (Document Level) \text{TMF Structure} = \text{Zones (Top Level)} \longrightarrow \text{Sections (Mid Level)} \longrightarrow \text{Artifacts (Document Level)} TMF Structure = Zones (Top Level) ⟶ Sections (Mid Level) ⟶ Artifacts (Document Level)
The 11 Core Zones of the TMF Reference Model +---------------------------------------------------------------------------------------------+
- | DIA TMF REFERENCE MODEL - 11 ZONES |
- +------------------------------------+--------------------------------------------------------+
- | Zone Number & Name | Representative Artifacts & Scope |
- +------------------------------------+--------------------------------------------------------+
- | Zone 01: Trial Management | Trial Oversight Plans, Meeting Minutes, Vendor Mgt |
- | Zone 02: Central Trial Documents | Core Protocol, Sample CRF, Investigator's Brochure |
- | Zone 03: Regulatory | Competent Authority Filings, Import Licenses, CTA |
- | Zone 04: IRB / IEC | Central/Local Ethics Approvals, Annual Reviews |
- | Zone 05: Site Management | Feasibility, 1572s, Site Training, DOAL, SIV/IMV/COV |
- | Zone 06: IP and Trial Supplies | IP Labeling, CoAs, Shipping/Receipt, Randomization |
- | Zone 07: Safety Reporting | Safety Management Plans, SUSARs, DSURs, CIOMS Logs |
- | Zone 08: Central & Local Labs | Lab Certifications, Reference Ranges, Sample Tracking |
- | Zone 09: Third Parties / Vendors | CRO Agreements, Central Readers, EDC Vendor Validation |
- | Zone 10: Data Management | Data Management Plan (DMP), CRF Completion Guidelines |
- | Zone 11: Statistics | Statistical Analysis Plan (SAP), Randomization Specs |
- +------------------------------------+--------------------------------------------------------+
By utilizing this standardized structure, sponsors, CROs, investigators, and regulatory auditors share a common vocabulary and filing logic, eliminating ambiguities during multi-center, multi-national trials.
2. Sponsor TMF vs. Investigator Site File (ISF / Regulatory Binder)
A fundamental concept tested on the ACRP-CP exam is the distinction between what is held by the sponsor versus what is maintained at the investigational site.
Comparison: Sponsor TMF vs. Investigator Site File (ISF)
- Attribute Sponsor Trial Master File (TMF) Investigator Site File (ISF / Binder)
- Primary Custodian Sponsor or delegated CRO Principal Investigator (PI) & Site Staff
Geographic Scope Global — compiles records across all countries and sites Local — contains records specific to that single site
Confidential Subject Data Prohibited. Must contain strictly pseudonymized / de-identified data. Maintained locally. Houses original signed ICFs, Subject ID Code List, medical records.
Vendor & Master Contracts Global CRO contracts, master insurance policies, vendor validation docs. Site-specific Clinical Trial Agreement (CTA) and site budget annex.
Blinded vs. Unblinded Contains unblinded randomization master lists in restricted unblinded sub-sections. Strictly blinded (except for designated unblinded site research pharmacist).
Staff Credentials Holds CVs, licenses, GCP certificates for all investigators globally. Holds CVs, licenses, DOAL, and training logs for site personnel only.
- The Confidentiality Firewall INVESTIGATOR SITE FILE (ISF) SPONSOR TRIAL MASTER FILE (TMF)
- [Site Secure Document Vault] [Global Enterprise Repository]
- +-------------------------------+ +--------------------------------+
- | * Original Signed ICFs | | * Redacted/De-identified Data |
- | * Subject ID Master Code List | ======X== | * Aggregate Safety Reports |
- | * Site Medical Charts / EHR | (NO PII) | * Central Vendor Validations |
- | * Site-Specific DOAL & Logs | | * Cross-Site Monitoring Logs |
- +-------------------------------+ +--------------------------------+
Under no circumstances may participant identifying information (names, personal addresses, social security numbers) cross the firewall into the sponsor TMF.
3. Electronic TMF (eTMF) & Electronic ISF (eISF) Systems
Modern clinical trials have transitioned from physical paper three-ring binders to cloud-based electronic Trial Master Files (eTMF) and electronic Investigator Site Files (eISF) . These electronic systems must comply with stringent regulatory frameworks, including FDA 21 CFR Part 11 and EMA Annex 11 .
Core Regulatory Expectations for eTMF / eISF Systems:
System Validation: Demonstrated evidence of Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) proving software reliability and data security.
Computer-Generated Audit Trails: Secure, computer-generated, time-stamped audit trails that independently record the date, time, operator, action (create, modify, view, delete), and reason for change for every artifact.
Role-Based Access Control (RBAC): Granular permission settings ensuring that unblinded personnel, blinded staff, CRA monitors, and QA auditors have strictly controlled access rights according to their authorized roles.
Contemporaneous Metadata Tagging: Every uploaded document must be indexed with standardized metadata attributes (e.g., Artifact Type, Country, Site ID, Document Date, Version, Expiration Date ).
Direct Regulatory Access: When regulatory authorities (FDA, EMA, MHRA) inspect a clinical trial, the eTMF/eISF system must provide inspectors with direct, independent, read-only access without vendor intervention or filtering.
4. Inspection Readiness & TMF Quality Metrics
Inspection readiness is the operating philosophy that a clinical trial must be organized and maintained at all times such that an unannounced regulatory inspection can take place tomorrow without requiring special remediation or clean-up. Inspection Readiness = Completeness + Timeliness + Quality (ALCOA+) \text{Inspection Readiness} = \text{Completeness} + \text{Timeliness} + \text{Quality (ALCOA+)} Inspection Readiness = Completeness + Timeliness + Quality (ALCOA+)
The Three Pillars of TMF Quality Management:
Completeness (Expected Document Lists - EDL):
Measuring the percentage of required milestones and expected artifacts that are actually present in the file.
Utilizing dynamic EDLs that adjust automatically based on study milestones (e.g., protocol amendment triggers expected revised ICFs, IRB approval letters, and training logs across all sites).
Timeliness (Filing Velocity):
Measuring the lag time between document creation/execution and final filing/QC in the TMF.
Industry standard KPIs target filing within 15 to 30 days of document execution. Chronic filing backlogs (filing documents 3–6 months after the fact) represent a critical quality vulnerability.
Quality (Artifact Review & ALCOA+ Checks):
Performing routine quality control checks on scanned artifacts to ensure legibility, complete page counts, presence of all required attachments, and valid dated signatures.
5. Common TMF / ISF Inspection Deficiencies & Form FDA 483 Observations
Regulatory inspections evaluate whether the documentation accurately reflects what happened during the trial. Common audit findings include:
Deficient Area Typical Inspection Finding Root Cause & Corrective Action (CAPA)
IRB / Ethics Approvals Protocol amendment implemented before documented IRB approval was received. Lack of site start-up control. Implement mandatory "greenlight" release checklists before dispensing under amendments.
Staff Delegation & Training Study coordinator or phlebotomist performed protocol procedures before being added to DOAL or trained. Failure to update DOAL contemporaneously. Require PI sign-off and documented training prior to system access.
Form FDA 1572 Lapses Sub-investigators actively treating subjects were omitted from Section 6 of Form FDA 1572. Poor PI oversight. Maintain monthly reconciliation between site DOAL, HR rosters, and Form FDA 1572.
IP Accountability Gaps Discrepancies between drug dispensing logs, return counts, and eCRF dose records; missing temperature logs. Inadequate pharmacy oversight. Implement dual-signature dispensing and automated continuous data logging.
Uncertified Translations Foreign-language patient questionnaires or ICFs used without certificate of translation accuracy. Vendor management failure. Require certified translation verification prior to IRB submission.